Since we found that both PERK and Nrf2 were upregulated with anlotinib treatment and the ROS production is important in anlotinib-induced apoptosis, we, therefore, considered that the increased expression of Nrf2 in anlotinib-treated PC cells would protect tumours from ROS injury and decreases the tumouricidal effect. The gene discussed is EIF2AK3; the disease is neoplasm.